But Lilly isn't alone in the market, and in the coming years, this space could become more crowded. Today, Lilly competes ...

The success of Eli Lilly’s Zepbound, a challenger to Novo’s Wegovy, has prompted comparisons to a similar scenario, when ...

Shares of Eli Lilly & Co. LLY slid 1.65% to $909.32 Thursday, on what proved to be an all-around favorable trading session ...

Japan is the second major market where LLY's Kisunla has been approved. The drug was first approved in the United States in ...

Eli Lilly said on Tuesday Japan's health ministry has approved donanemab, its drug for Alzheimer's disease, providing ...

An analysis of Eli Lilly's stock reveals high premium, overvaluation concerns and a low dividend yield. LLY is rated hold due ...

Eli Lilly & Co. closed $48.10 short of its 52-week high ($972.53), which the company achieved on August 22nd.

Eli Lilly's long-term growth prospects are strong with improved supply, new growth opportunities, and competitive positioning ...

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

Sen. Bernie Sanders’ aggressive targeting of Danish drugmaker Novo Nordisk’s Ozempic and Wegovy pricing, and not Eli Lilly’s ...

To fight off compounding pharmacies, Eli Lilly wants access to medical records of patients who used copycat products.

Investors with a lot of money to spend have taken a bullish stance on Eli Lilly LLY. And retail traders should know. We ...